Abivax

ABVX

FR0012333284

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-12 am EST			After hours 03:59:53 pm
104.00 ^EUR	+5.91%		103.80	-0.19%

Jan. 20	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 20	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

France Says Yet to Receive Investment Screening Dossier from Lilly Over Potential Abivax Bid

Published on 01/12/2026 at 11:10 am EST

MT Newswires

Latest news about Abivax

Jan. 20	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 20	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
Jan. 20	Abivax CEO Says No Talks on Acquisition Deal Amid Reported Lilly Interest	MT
Jan. 20	Abivax CEO Plays Down Eli Lilly Takeover Talk	MT
Jan. 20	Abivax CEO dismisses 'noise' around rumored Eli Lilly bid	RE
Jan. 20	Euro-American Tensions Continue to Weigh on Stock Markets
Jan. 20	Wise and Virbac Benefit from Quarterly Results, Valneva and Logitech Slide
Jan. 20	Renault, Abivax, Virbac... Stocks to Watch Today in Paris
Jan. 20	Abivax May Have a New... European Suitor
Jan. 15	Abivax, Top Gainer on the SBF 120 at Midday Thursday, January 15, 2026
Jan. 14	Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
Jan. 14	Stifel Sees Nearly 37% Upside Potential for Abivax
Jan. 14	Historic Morning Record for the CAC 40
Jan. 13	French Government Says Eli Lilly Made No Contact Regarding Abivax Takeover	MT
Jan. 12	European Stocks Close Mostly Higher in Monday Trading; BHP Not Planning to Bid on Glencore	MT
Jan. 12	France Says Yet to Receive Investment Screening Dossier from Lilly Over Potential Abivax Bid	MT
Jan. 12	France denies contact with Eli Lilly over reported $17.5 billion Abivax deal	RE
Jan. 12	French Government Says Eli Lilly Made No Contact Regarding Abivax Takeover	MT
Jan. 12	Analyst recommendations: Exxon Mobil, AbbVie, Eli Lilly, JD Sports…
Jan. 12	Abivax Surges on Takeover Rumors, French Finance Ministry Not Informed	RE
Jan. 12	France has had no request for investment approval in biotech Abivax - official	RE
Jan. 12	France: Bercy Not Informed of Any Request Regarding Abivax, Sought After by Eli Lilly	RE
Jan. 12	Sector Update: Health Care Stocks Lower Pre-Bell Monday	MT
Jan. 12	Fed Chair Powell Faces US DOJ Criminal Probe, Equity Futures Waver Pre-Bell	MT
Jan. 12	Independence, Under Review

Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 20 - European Crohn and Colitis Organisation Congress - Abstract No - DOP057

More about the company